 AIkido Pharma Inc. Nasdaq: AIKI AIkido or the Company today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic. As previously announced, on April 13, 2020, AIkido executed a Master License Agreement with the University of Maryland, Baltimore UMB, covering certain antiviral compounds discovered by UMB. 